
It was another busy week for Australia's top brokers. This has led to the release of a number of broker notes.
Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:
According to a note out of Macquarie, its analysts have retained their outperform rating on this appliance manufacturer's shares with a trimmed price target of $37.10. Macquarie has been looking at industry data and believes it is favourable for Breville and suggests that it could be outperforming peers. The broker highlights that this is being driven by growth from its coffee business, as well as new products and new markets. Overall, Macquarie believes this leaves Breville well-placed for annual growth of 10%+ through to FY 2028. The Breville share price ended the week at $26.28.
A note out of UBS reveals that its analysts have retained their buy rating and $302.00 price target on this hearing solutions company's shares. UBS believes that recent share price weakness has created an attractive buying opportunity for investors. This is especially the case given how the broker believes Cochlear's new next-generation cochlear implant platform, Nexa, will underpin a strong earnings recovery. The broker believes that with limited competition, Cochlear is well-placed to win market share. And while there are concerns over gene therapies, UBS doesn't believe this is something that will impact its near term performance. The Cochlear share price was fetching $170.23 at Friday's close.
Another note out of UBS reveals that its analysts have retained their buy rating and $2.20 price target on this lithium miner's shares. UBS is feeling positive about lithium and believes now could be a good time for investors to consider a position in the industry. This is because UBS sees potential for another upcycle for lithium prices. It suspects that surging oil prices and supply disruptions caused by the war in the Middle East could be good news for lithium. It feels that the impact this is having on the fuel market could lead to increased demand for electric vehicles and lithium for batteries. In fact, the broker sees potential for the spodumene price to reach US$4,000 per tonne by the end of the year. The Liontown share price ended the week at $1.76.
The post Top brokers name 3 ASX shares to buy next week appeared first on The Motley Fool Australia.
Motley Fool contributor James Mickleboro has positions in Cochlear. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026